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was highest among patients who were using oral chemotherapy agents (34.1%). The 
number of non-adherent behaviors was significantly associated with a decrease 
in functional well-being (FWB; b= -1.40), FACT-G total score (b= -3.01), FACT-B total 
score (b= -3.92), and FACT trial outcome index (FACT-TOI; b= -2.98) (all p< .05). These 
relationships were stronger when focusing on respondents who were using an oral 
chemotherapy agent (n= 44) (bs= -3.14, -7.37, -6.11, -8.63 for FWB, FACT-G, FACT-B, and 
FACT-TOI, respectively). ConClusions: Approximately a third reported engaging 
in non-adherent behavior. These behaviors were associated with significant decre-
ments in health status, suggesting improvements in adherence could correspond 
to quality of life benefits to the patient.
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objeCtives: Utility values used in economic evaluations of new products reflect 
the strength of preference for the health related quality of life (HRQL) of a given 
health state. These can be captured using the time trade-off (TTO) methodology. 
The aim of this study was to elicit societal utility values for states related to chronic 
lymphocytic leukemia (CLL). Methods: Nine health states were developed fol-
lowing a literature review, interviews with patients (n= 6) and clinicians (n= 5), and 
review by lay members of the public (cognitive debriefing; n= 5). These health states 
were: progression free survival (PFS) on initial intravenous (IV) therapy; PFS on ini-
tial oral therapy; PFS on initial therapy with increased hospital visits; PFS without 
therapy; progression after 1st line therapy; PFS on 2nd line therapy; PFS without 2nd 
line therapy (post 2nd line treatment, but not currently receiving therapy); further 
progression (disease progression after 2 lines of treatment); and relapsed lines of 
treatment (≥ 3 lines of treatment). One hundred members of the UK general public 
valued each health state using the TTO methodology. Results: PFS states were 
the least burdensome: PFS without therapy (mean utility= 0.82); PFS on initial oral 
therapy (0.71); PFS on initial IV therapy (0.67), apart from PFS on initial therapy with 
increased hospital visits (0.55). Mean utility for disease progression after 1st line 
therapy was 0.66 and for PFS without 2nd line therapy was 0.71; further progres-
sion (0.59), PFS on 2ndline therapy (0.55), and relapsed lines of treatment (0.42) had 
greater burdens. ConClusions: The results show the weights that the general 
public place on CLL states, underlining the value in maintaining PFS for as long as 
possible. Findings also highlight the extent to which HRQL declines following first 
line progression. These findings can support the estimation of quality adjusted life 
years associated with treatments for CLL.
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objeCtives: Health-state utilities values (HSUVs) are an essential component for 
cost-utility analysis (CUA). The aim of this review was to systematically identify 
utility weights associated with advanced gastric (GC), oesophageal (OC), or gastro-
oesophageal junction (GEJ) adenocarcinoma. Methods: Embase, MEDLINE and 
Cochrane databases (accessed September 2013) were interrogated for relevant 
studies using a predefined search strategy. Studies eligible for inclusion included 
those reporting HSUVs using direct (standard gamble [SG] and time-trade-off 
[TTO]) and indirect methods (such as EuroQol 5D [EQ-5D], short-form 6D [SF-6D] 
and 15D). Results: A total of 703 publications were identified, of which eight met 
the inclusion criteria (GC, n= 2; mixed population [MP], n= 4; OC, n= 2). The most 
commonly used instrument to estimate HSUVs was the EQ-5D (n= 7): post-chem-
otherapy (GC, 0.550 [n= 1]; MP, 0.66-0.76 [n= 1]); progression-free survival (GC, 0.73 
[n= 1]); weight loss (MP, 0.52-0.69 [n= 2]); patient’s valuation of health state (OC, 
0.60-0.93 depending on stage [n= 1]); dysphagia-associated (OC, 0.39-0.82, depending 
on score [n= 1]); societal valuation of health state (OC, 0.15-0.77 [n= 1]); inoperable 
OC/GEJ (MP, 0.63 [n= 1]). One study derived utilities using the SF-6D and the 15D 
(post-chemotherapy in GC patients, 0.606 and 0.685, respectively). In two studies 
the TTO method was used to determine the following HSUVs: patient’s valuation of 
health state (OC, 0.52-0.80 depending on stage [n= 1]); societal valuation of health 
state (0.15-0.77, [n= 1]); dysphagia-associated (OC, 0.25-0.86, depending on score 
[n= 1]); inoperable OC (0.08-0.66, depending on health state [n= 1]). Only one study 
determined HSUVs for inoperable OC according to the SG method (0.08-0.78, depend-
ing on health state). ConClusions: There are limited data estimating HSUVs in 
patients with advanced GC, OC or GEJ. Comparisons are confounded by heteroge-
neity across patient and study characteristics in the identified studies. Further 
research into HSUVs associated with advanced gastric/oesophageal cancers is 
required in order to improve the evidence available for use in CUAs.
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objeCtives: To evaluate the quality of life (QoL) of CML patients using the EQ-5D-5L 
instrument by gathering the patient’s perspective of how, and to what extent, their 
therapy impacts QoL. Methods: Patients from the Huntsman Cancer Institute com-
CaNCer – Patient-reported outcomes & Patient Preference Studies
PCN137
treatmeNt PatterNS aNd PerSiSteNCe amoNG PatieNtS treated witH 
StivarGa
Chastek B.1, Seal B.S.2, Rietschel P.2
1OptumInsight, Eden Prairie, MN, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA
objeCtives: Examine baseline treatment patterns and persistence among patients 
diagnosed with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal 
tumor (GIST) and treated with Stivarga® (regorafenib). Methods: Adult patients 
treated with Stivarga from 9/27/12-7/31/13 were identified from a large national 
US claims database. Patients were retained if they were continuously enrolled in 
the health plan for ≥ 6 months before the initial (index) fill (baseline period) and 
≥ 1 month after the index fill (follow-up period). Patients were required to be diag-
nosed with mCRC or GIST, be 18+ years old, and have non-missing demographic 
information. Follow-up persistence with Stivarga was identified based on a gap in 
therapy of at least 30 days. The use of chemotherapy in the baseline, the last regimen 
received before initiating Stivarga, and the amount of time between receipt of last 
chemotherapy and Stivarga initiation was identified. Results: 283 patients were 
treated with Stivarga and 235 met all inclusion criteria. Mean age was 61.6 years, 
66.4% were female, and 38.7% were Medicare Advantage patients. Mean baseline 
length was 4.2 years (median: 3.3 years). Mean follow-up length was 4.5 months. 
Baseline chemotherapy use was observed in 97.5% of patients; 89.5%, 72.9%, and 
79.9% of patients received irinotecan, oxaliplatin or bevacizumab, respectively. The 
most common regimens prior to Stivarga were FOLFIRI (12.7%), FOLFIRI+BEV (10.0%), 
and Irinotecan+Cetuximab (8.7%). On average, patients had a gap of 85 days from 
receipt of last chemotherapy until initiating Stivarga; 50% initiated within 30 days 
and 25% initiated after more than 84 days. Patients received 2.5 fills of Stivarga and 
were persistent for 69.5 days, on average. 37.5% of patients were persistent through 
the end of their follow-up. ConClusions: Most Stivarga-treated mCRC or GIST 
patients received chemotherapy in the 3 months prior to initiating Stivarga. At least 
half of patients were persistent for at least 8 weeks.
PCN138
ComPariSoN of adHereNCe rateS BetweeN oral CaPeCitaBiNe aNd 
iNtraveNoUS CHemotHeraPy reGimeNS to treat metaStatiC ColoN 
CaNCer
Seal B.S.1, Anderson S.2, Cameron J.2, Shermock K.M.3
1Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA, 2Bayer HealthCare Pharmaceuticals, 
Inc., Pine Brook, NJ, USA, 3The Johns Hopkins Medical Institutions, Baltimore, MD, USA
objeCtives: To compare adherence rates to oral versus intravenous (IV) chemother-
apy regimens to treat metastatic colorectal cancer (CRC). Methods: A retrospective 
analysis was performed using the OptumInsight Oncology claims database. Patients 
aged 18 years and older, diagnosed with metastatic CRC between July 1, 2004 and 
December 31, 2010, who were insured by a commercial health plan were included. 
Adherence was assessed using the medication possession ratio (MPR), calculated 
as the proportion of days a patient was covered by their chemotherapy regimen, 
according to NCCN guidelines, from the first to the last cycle/prescription of that 
regimen. Comparisons of MPR between the groups were performed by multivariate 
logistic regression, using the threshold of MPR> 0.8 to define high adherence; and 
by multivariate linear regression treating MPR as a continuous variable. Results: 
A total of 9,964 chemotherapy regimens in cycles in 3,367 patients were analyzed. 
The most common regimens were IV FOLFOX (n= 1,710), oral capecitabine (n= 1,328), 
and IV FOLFOX+bevacizumab (n= 1,100). Overall, adherence was significantly higher 
for IV regimens (mean MPR = 0.88) versus capecitabine oral regimens (mean MPR 
= 0.80, p< 0.001). Additionally, a significantly higher proportion of patients receiv-
ing IV regimens (77%) achieved an MPR > 0.8 compared with patients receiving 
capecitabine chemotherapy (53%, p< 0.001). These differences persisted when 
stratifying by line of chemotherapy, age, and disease severity (measured using the 
weighted Charlson index). In multivariate logistic regression, oral chemotherapy 
regimens were associated with an odds ratio of 0.33 regarding achieving an MPR of 
> 0.8. Similarly, in multivariate linear regression capecitabine oral chemotherapy 
regimens were associated with a significant decrement in MPR (beta coefficient = 
-0.084, p< 0.001). ConClusions: Capecitabine oral chemotherapy regimens were 
associated with a significantly lower adherence rate compared with IV regimens in 
metastatic CRC patients. The clinical impact of the observed differences is unknown.
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objeCtives: The increasing availability of treatment options for metastatic breast 
cancer (mBC), particularly oral chemotherapy agents, has elevated the importance 
of adherence. This study sought to address the relationship between non-adherence 
and quality of life among women with mBC. Methods: A cross-sectional Internet 
survey was administered to 181 women diagnosed with mBC who had prior expe-
rience with either a taxane, paclitaxel, or docetaxel. Demographic, health history, 
treatment history (e.g., current use of chemotherapy [oral or IV], radiation therapy, 
or hormone therapy) and quality of life in the past 7 days (using the FACT-B) infor-
mation was collected. Patients were asked whether they had skipped/missed a 
dose and the reason for doing so (e.g., tolerability of side effects, reduce cost). The 
number of different non-adherence reasons was used to predict FACT-B scores using 
regression modeling, controlling for demographics and health history. Subgroup 
analyses were conducted among those using IV and oral chemotherapy agents, sep-
arately. Results: The mean age was 52.2 years and 93.9% were non-Hispanic white. 
42.0% and 24.3% of respondents were currently using an IV and oral chemotherapy 
agent, respectively. Across all treatments, 34.8% of respondents reported engaging 
in non-adherent behavior. Aside from hormone therapy (43.0%), non-adherence 
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objeCtives: Among the bone-targeted agents (BTAs) currently approved for the pre-
vention of skeletal-related events (SREs), several characteristics may be considered 
by physicians when making treatment decisions. This study evaluated Canadian 
physicians’ treatment preferences for BTAs used to prevent SREs in patients with 
bone metastases from solid tumors. Methods: Physicians treating patients with 
bone metastases from solid tumors completed a web-enabled discrete-choice 
experiment survey consisting of 10 choices between pairs of hypothetical medica-
tion profiles for patient with either breast or prostate cancer. Each hypothetical 
medication profile included five attributes within a pre-defined range (primarily 
based on prescribing information): months until first SRE (10, 18 and 28 months); 
months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis 
of the jaw (ONJ; 0%, 1% and 5%); annual risk of renal impairment (0%, 4% and 10%); 
and mode of administration (oral tablet, subcutaneous injection, 15-minute infu-
sion and 120-minute infusion). Choice questions were based on an experimental 
design with known statistical properties. The survey was pretested with 8 physicians 
using open-ended interviews. A main-effects random parameters logit model was 
used to analyze the data. Results: A total of 200 Canadian physicians completed 
the survey. Over the attribute levels included, months until first SRE, the risk of 
renal impairment, and months until worsening of pain were the most important 
attributes. For those attributes, better levels (outcomes) were significantly preferred 
to worse levels (P < 0.05). For mode of administration, subcutaneous injection was 
preferred over infusion regardless of duration (P < 0.05). ConClusions: When 
making treatment decisions regarding choice of BTA for patients with bone metas-
tases, delaying the onset of SREs and managing the risk of renal impairment are the 
primary considerations for Canadian physicians. Also, respondents had well-defined 
preferences for subcutaneous injections over infusion every 4 weeks.
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objeCtives: It is unclear whether the conceptual coverages of the instruments 
available to evaluate the health-related quality of life (HRQoL) of multiple myeloma 
(MM) patients are adequate in the relapsed or refractory (R/R) setting, with respect 
to the FDA’s patient-reported outcome (PRO) guidance. To address this uncertainty, 
we conducted qualitative interviews with R/R MM patients and compared the results 
to the conceptual frameworks of three existing instruments. Methods: Two con-
secutive sets (n= 15 and n= 8) of qualitative concept elicitation (CE) interviews were 
conducted with R/R MM patients in the U.S. The concepts reported were compared 
with the conceptual frameworks of the EORTC QLQ-C30 and QLQ-MY20, FACT-MM, 
and MDASI-MM. In addition, a conceptual model was devised based on the results of 
these interviews, and an analysis of the relative timing (with respect to treatment/
disease course) of the reported symptoms and impacts was conducted. Results: 
A total of 23 R/R MM patients (age range= 50 to 89 years; mean age= 66.7±10.1 years; 
male= 56.5%) participated in the CE interviews. A total of 37 symptom concepts 
and 55 HRQoL impacts were reported. Of the six symptom concepts reported by 
> 2 patients, five (83.3%) were covered by the QLQ-C30 and MY-20, three (50.0%) by 
the FACT-MM, and three (50.0%) by the MDASI-MM. Of the 23 impacts reported by 
> 2 patients, 14 (60.9%) were covered by the QLQ-C30 and MY-20, 9 (39.1%) by the 
FACT-MM, and 7 (30.4%) by the MDASI-MM. Analysis of the timing of symptom/
impact reporting revealed that the majority of concepts noted by > 2 MM patients 
were present both pre- and post-relapse. ConClusions: These findings indicate 
that the EORTC QLQ-C30 and QLQ-MY20 instruments are appropriate for captur-
ing the symptom and impact domains most often reported by R/R MM patients, 
although room may remain for improvement in assessing functional impacts at 
the conceptual level in this population.
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objeCtives: To perform a qualitative patient interview study using an internet-
based digital patient platform for recruitment and telephone and webcam for 
interviews. Methods: To design the qualitative study we followed the steps out-
lined in the ISPOR PRO Good Research Practices Task Force Report: Part 1 (Patrick 
et al, 2011). Briefly, a qualitative interview guide was developed and approved by 
IRB. Participants were recruited, consented, enrolled, and interviewed online. Each 
interview was audio recorded and transcribed. Analysis of the qualitative data was 
performed by experienced market researchers. Results: Screening, demographic, 
and medical information was gathered directly from patients online, via the inter-
net, with no interaction from the patient’s physician(s) or site. Existing members 
of MediGuard, an online free medication monitoring service, were sent an email 
invitation to participate in the study. Members who choose to click on the link were 
directed to a website where they accessed information regarding the study, provided 
consent to participate, self-screened for eligibility, and reported baseline character-
istics. Consented participants were contacted via phone to schedule a time to par-
ticipate in an individual interview via telephone or webcam. Interviews were audio 
recorded, and lasted 60-75 minutes. 17 patients were interviewed. ConClusions: 
Recruiting and interviewing patients via the internet and phone is a feasible, faster, 
and potentially lower cost alternative to face to face interviews. Some benefits of 
direct to patient research include potential to reduce patient travel burden to a study 
pleted the EQ-5D-5L. Inclusion criteria were current chronic phase of CML, visits after 
June 2012, and age ≥ 18 years at diagnosis. The analysis included descriptive statistics 
of the sample population and derivation of a utility value for each patient. Kruskal 
Wallis test was conducted to compare the utility values for non-parametric data, and 
t test was conducted for parametric data. A utility value of 0 implies death, while a 
value of 1 implies full health. Results: Out of the 81 questionnaires that were mailed 
33 (40.7%) were returned. Three returned questionnaires were excluded due to failure 
to complete the instrument, and one patient passed away. Of the 29 patients in the 
final sample, there are 15 males, the mean age was 54.3±15.0 years, the mean utility 
was 0.79±0.15, and the mean duration of CML was 5.1±3.6 years. For current CML treat-
ments, 3 patients had undergone stem cell transplantation (SCT), 25 patients were 
receiving tyrosine kinase inhibitors (TKIs), and one patient discontinued medication 
due to adverse events. Overall, the mean utility difference between SCT and TKIs was 
not statistically significant (0.72± 0.15 vs. 0.80 ± 0.15, p= 0.35). Among TKIs, Imatinib 
had the highest utility scores (0.88±0.14, n= 10), followed by ponatinib (0.83±0.15, n= 3), 
nilotinib (0.81±0.04, n= 3), dasatinib (0.72±0.12, n= 8), and bosutinib (0.48, n= 1). There 
was no statistical difference in utilities in patients who received one line of treat-
ment (0.83±0.15, n= 13) vs. multiple lines (0.76±0.15, n= 12, p= 0.22). ConClusions: 
Although the study population was small, our results indicate that current US CML 
patients have good QoL scores. A larger sample size is needed for further research.
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objeCtives: Carcinoid tumors are a type of neuroendocrine tumor (NET), most 
often occurring in the gastrointestinal tract. These tumours are rare and difficult 
to identify, since symptoms are often associated with other conditions. Once cor-
rectly diagnosed, many symptomatic patients are treated with Sandostatin LAR. This 
study sought to identify the typical NET patient journey, from onset of symptoms to 
diagnosis and treatment. Methods: 75 NET patients that are currently treated with 
Sandostatin LAR were interviewed by telephone using a 30-minute structured ques-
tionnaire comprised of a mix of closed-ended and open-ended questions. Results: 
More than three quarters (76%, n= 57) of patients presented with symptoms prior 
to NET diagnosis. 74% of these symptomatic patients (n= 42) were first seen by a 
general practitioner / family doctor. However NET was recognised within 1 year in 
only 51% of cases (n= 29), while in the remaining 49% of cases it took more than a 
year to correctly diagnose NET. Out of all asymptotic patients (n= 18), in 39% cases 
(7/18*100%; n= 7) the tumors were found incidentally while the patient was under-
going treatment for another condition, while in 33% cases (6/18*100%; n= 6) NET 
condition was discovered due to abnormal test results. Two-fifths (43%, n= 32) of 
respondents were misdiagnosed prior to receiving NET diagnosis, with 53% (n= 17) 
of misdiagnosed cases persisting for more than 1 year. Overall, 83% of the sample 
saw 2 or more physicians before NET was diagnosed. ConClusions: The results of 
this research indicate that Canadian patients can experience significant delays in 
the correct diagnosis and appropriate treatment of NET. This is attributable in part 
to the nonspecific nature of the signs and symptoms of NET, but also due to a lack 
of awareness of NET among frontline physicians and the general public.
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objeCtives: To examine relative preferences for symptoms, treatment-related side-
effects and progression-free survival (PFS) in women with ovarian cancer using 
a discrete choice experiment (DCE). Methods: A pilot study was conducted of 
women with advanced or recurrent ovarian cancer. In the DCE, participants were 
asked to choose between two treatment scenarios, modeled on characteristics of 
standard intravenous (IV) and intraperitoneal/intravenous (IP/IV) treatments for 
newly diagnosed ovarian cancer. Each scenario included 7 attributes with 2-3 levels 
each: mode of administration (IV versus IP/IV); visit frequency (one per week, two 
per 3 weeks, one per 3 weeks); treatment-related abdominal symptoms, neuropathy, 
fatigue, nausea, and vomiting; and PFS (15, 18, 21 and 24 months). We used a bal-
anced overlap design with 10 versions of the survey. Each participant evaluated 12 
random choice and one fixed-choice scenario. Mixed logit regression modeled par-
ticipant’s choices as a function of attribute levels. Results: 95 women completed 
the survey. Mean age was 57 and 81% were Caucasian. Half (47%) had experienced 
disease recurrence and 49% were currently receiving chemotherapy. Compared to 
scenarios with 15 months of PFS, the relative odds that a participant would choose 
a scenario with 18, 21 and 24 months of PFS were 1.5 (p= 0.01), 3.4 (p< 0.001) and 7.5 
(p< 0.001), respectively. Assuming a linear relationship with PFS, on average, patients 
were willing to tradeoff 6.7 months of PFS for an improvement from severe to mild 
nausea and vomiting during treatment, 5.0 months of PFS for an improvement from 
severe to mild neuropathy, and 3.7 months of PFS for an improvement from severe to 
moderate abdominal symptoms. ConClusions: Progression-free survival time is 
the most important factor in determining preferences for chemotherapy regimens. 
However, women with ovarian cancer were willing to give up significant amounts 
of PFS time for marked reductions in the severity of treatment-related side effects.
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